Next 10 |
2024-06-18 13:18:09 ET More on Celldex Celldex Therapeutics: Rising High, With Room For Further Growth Celldex initiated to outperform at Wolfe on barzolvolimab for skin disease Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celld...
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-11 12:56:49 ET More on Celldex Celldex Therapeutics: Rising High, With Room For Further Growth Seeking Alpha’s Quant Rating on Celldex Historical earnings data for Celldex Financial information for Celldex Read the full article on See...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...
2024-06-10 15:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
- Clinically meaningful and statistically significant improvements across multiple angioedema measurements and barzolvolimab dose groups - - Sustained activity with rapid onset within 2 weeks - - Data further support barzolvolimab clinical benefit to patients with CSU - HAMPTON,...
HAMPTON, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced that the first patient has been dosed in the Company’s Phase 2 subcutaneous study of barzolvolimab in prurigo nodularis (PN). Barzolvolimab is a humanized monoclonal antibody that speci...
2024-05-10 10:44:11 ET Summary Celldex Therapeutics is a biopharmaceutical company with a strong pipeline of potential treatments. The company has a solid financial outlook, which is a positive factor for investors. If you respect the risks of investing based on phase 2 data, ...
2024-05-09 23:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-07 18:15:02 ET Guggenheim analyst issues UNDERPERFORM recommendation for CLDX on May 7, 2024 04:00PM ET. The previous analyst recommendation was Underperform. CLDX was trading at $42.21 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
News, Short Squeeze, Breakout and More Instantly...
Celldex Therapeutics Inc. Company Name:
CLDX Stock Symbol:
NASDAQ Market:
Celldex Therapeutics Inc. Website:
2024-06-17 18:00:08 ET Alex Thompson from Stifel Nicolaus issued a price target of $58.00 for CLDX on 2024-06-17 16:15:00. The adjusted price target was set to $58.00. At the time of the announcement, CLDX was trading at $34.91. The overall price target consensus is at $...
2024-06-10 19:15:02 ET Wolfe Research analyst issues OUTPERFORM recommendation for CLDX on June 10, 2024 06:14PM ET. CLDX was trading at $34.64 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 1 -...
2024-06-10 15:32:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...